PROS1 and COVID-19: In good agreement with published data from SARS-CoV-2 proteome-based peptide arrays61, we found that linear peptides from these studies that contained our resolved epitopes on S protein showed differential seroreactivity in naïve, mild and severe COVID-19 samples (Fig. S3).